Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q37830562 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000314.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q37830562 | ||
| 024 | ‡a 0000-0002-6531-9595 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q37830562 | ||
| 100 | 0 | ‡a Larry D Anderson ‡c investigador ‡9 ast | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a ল্যারি ডি অ্যান্ডারসন ‡c গবেষক ‡9 bn | |
| 400 | 0 | ‡a Larry D Anderson ‡c researcher ‡9 en | |
| 400 | 0 | ‡a Larry D Anderson ‡c investigador ‡9 es | |
| 400 | 0 | ‡a Larry D. Anderson ‡c ricercatore ‡9 it | |
| 400 | 0 | ‡a Larry D Anderson ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. | ||
| 670 | ‡a Author's Adoptive T-cell therapy for B-cell malignancies | ||
| 670 | ‡a Author's Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality | ||
| 670 | ‡a Author's DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation | ||
| 670 | ‡a Author's Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine | ||
| 670 | ‡a Author's Esophago-respiratory fistula. | ||
| 670 | ‡a Author's Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses | ||
| 670 | ‡a Author's HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells | ||
| 670 | ‡a Author's Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. | ||
| 670 | ‡a Author's Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy | ||
| 670 | ‡a Author's Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma | ||
| 670 | ‡a Author's Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease | ||
| 670 | ‡a Author's Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect. | ||
| 670 | ‡a Author's Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. | ||
| 670 | ‡a Author's Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | ||
| 670 | ‡a Author's Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease | ||
| 670 | ‡a Author's Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene | ||
| 670 | ‡a Author's Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial | ||
| 670 | ‡a Author's Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma | ||
| 670 | ‡a Author's Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. | ||
| 909 | ‡a (orcid) 0000000265319595 ‡9 1 | ||
| 919 | ‡a her2neupeptidespecificityintherecognitionofhlaa2bynaturalkillercells ‡A HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells ‡9 1 | ||
| 919 | ‡a ibrutinibaloneorwithdexamethasoneforrelapsedorrelapsedandrefractorymultiplemyelomaphase2trialresults ‡A Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. ‡9 1 | ||
| 919 | ‡a ibrutinibusecomplicatedbyprogressivemultifocalleukoencephalopathy ‡A Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy ‡9 1 | ||
| 919 | ‡a pretransplanttumorantigenspecificimmunizationofallogeneicbonemarrowtransplantdonorsenhancesgraftversustumoractivitywithoutexacerbationofgraftversushostdisease ‡A Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease ‡9 1 | ||
| 919 | ‡a identificationofmagec1ct7epitopesfortcelltherapyofmultiplemyeloma ‡A Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma ‡9 1 | ||
| 919 | ‡a immunizationofallogeneicbonemarrowtransplantrecipientswithtumorcellvaccinesenhancesgraftversustumoractivitywithoutexacerbatinggraftversushostdisease ‡A Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease ‡9 1 | ||
| 919 | ‡a targetingbcellmaturationantigenwithgsk2857916antibodydrugconjugateinrelapsedorrefractorymultiplemyelomabma117159adoseescalationandexpansionphase1trial ‡A Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial ‡9 1 | ||
| 919 | ‡a understandingtherelationshipbetweencarevolumeandclinicaloutcomesinmultiplemyeloma ‡A Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. ‡9 1 | ||
| 919 | ‡a triplettherapytransplantationandmaintenanceuntilprogressioninmyeloma ‡A Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma ‡9 1 | ||
| 919 | ‡a nonmyeloablativeallogeneichematopoieticcelltransplantationforrelapsedorrefractorywaldenstrommacroglobulinemiaevidenceforagraftversuslymphomaeffect ‡A Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect. ‡9 1 | ||
| 919 | ‡a phase1trialofibrutinibandcarfilzomibcombinationtherapyforrelapsedorrelapsedandrefractorymultiplemyeloma ‡A Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ‡9 1 | ||
| 919 | ‡a peptideprimednaboostimmunizationprotocolprovidessignificantbenefitsasanewgenerationaβ42dnavaccineforalzheimerdisease ‡A A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. ‡9 1 | ||
| 919 | ‡a successfultreatmentofrelapsedandrefractoryextramedullaryacutepromyelocyticleukemiawithtamibarotene ‡A Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene ‡9 1 | ||
| 919 | ‡a adoptivetcelltherapyforbcellmalignancies ‡A Adoptive T-cell therapy for B-cell malignancies ‡9 1 | ||
| 919 | ‡a bonemarrowtransplantconditioningintensifiedwithliposomalclodronatetoeliminateresidualhostantigenpresentingcellsfailstoameliorategvhdandincreasesperibmtmortality ‡A Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality ‡9 1 | ||
| 919 | ‡a dnaimmunizationagainstamyloidbeta42hashighpotentialassafetherapyforalzheimersdiseaseasitdiminishesantigenspecificth1andth17cellproliferation ‡A DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation ‡9 1 | ||
| 919 | ‡a enhancementofgraftversustumoractivityandgraftversushostdiseasebypretransplantimmunizationofallogeneicbonemarrowdonorswitharecipientderivedtumorcellvaccine ‡A Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine ‡9 1 | ||
| 919 | ‡a esophagorespiratoryfistula ‡A Esophago-respiratory fistula. ‡9 1 | ||
| 919 | ‡a pomalidomidebortezomibanddexamethasoneformultiplemyelomapreviouslytreatedwithlenalidomideoptimismmoutcomesbypriortreatmentat1relapse ‡A Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse ‡9 1 | ||
| 919 | ‡a ganciclovirchemoablationofherpesthymidinekinasesuicidegenemodifiedtumorsproducestumornecrosisandinducessystemicimmuneresponses ‡A Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 SUDOC|153810181 | ||
| 996 | ‡2 LC|n 98801274 | ||
| 996 | ‡2 SUDOC|15757122X | ||
| 996 | ‡2 ISNI|0000000029360449 | ||
| 996 | ‡2 ISNI|0000000053449865 | ||
| 996 | ‡2 RERO|A011638654 | ||
| 996 | ‡2 LC|no2006010224 | ||
| 996 | ‡2 LC|no2001095722 | ||
| 996 | ‡2 CAOONL|ncf10196866 | ||
| 996 | ‡2 ISNI|0000000049981760 | ||
| 996 | ‡2 LC|no2008186341 | ||
| 996 | ‡2 RERO|A002928380 | ||
| 996 | ‡2 J9U|987007359960905171 | ||
| 996 | ‡2 LC|no 98036950 | ||
| 996 | ‡2 NTA|131056867 | ||
| 996 | ‡2 RERO|A024456242 | ||
| 996 | ‡2 LC|n 88067339 | ||
| 996 | ‡2 ISNI|0000000084315616 | ||
| 996 | ‡2 SUDOC|260544663 | ||
| 996 | ‡2 LC|n 79088953 | ||
| 996 | ‡2 LC|nr 93015753 | ||
| 996 | ‡2 LC|n 2003072367 | ||
| 996 | ‡2 LC|n 88042837 | ||
| 996 | ‡2 LC|no2010150088 | ||
| 996 | ‡2 CAOONL|ncf11426922 | ||
| 996 | ‡2 LC|n 2001017416 | ||
| 996 | ‡2 PLWABN|9810629462705606 | ||
| 996 | ‡2 ISNI|0000000024564020 | ||
| 996 | ‡2 BNF|12569728 | ||
| 996 | ‡2 LC|no2014016383 | ||
| 996 | ‡2 SUDOC|035007524 | ||
| 996 | ‡2 ISNI|0000000048364517 | ||
| 996 | ‡2 CAOONL|ncf10125682 | ||
| 996 | ‡2 J9U|987007413427005171 | ||
| 996 | ‡2 LC|no2017039238 | ||
| 996 | ‡2 LC|n 2003127152 | ||
| 996 | ‡2 LC|no2007117779 | ||
| 996 | ‡2 NII|DA10662566 | ||
| 996 | ‡2 LC|n 97095902 | ||
| 996 | ‡2 ISNI|0000000084544312 | ||
| 996 | ‡2 LC|n 80121569 | ||
| 996 | ‡2 ISNI|0000000047256821 | ||
| 996 | ‡2 LC|n 2008028212 | ||
| 996 | ‡2 LC|n 88635866 | ||
| 996 | ‡2 BNCHL|10000000000000000146642 | ||
| 996 | ‡2 BIBSYS|99044584 | ||
| 996 | ‡2 ISNI|0000000073949613 | ||
| 996 | ‡2 LIH|LNB:CC2_k_;=BJ | ||
| 996 | ‡2 CAOONL|ncf13717403 | ||
| 996 | ‡2 DNB|1019349549 | ||
| 996 | ‡2 DNB|1104393549 | ||
| 996 | ‡2 CAOONL|ncf10249346 | ||
| 996 | ‡2 SUDOC|165931523 | ||
| 996 | ‡2 LC|no2015092288 | ||
| 996 | ‡2 JPG|500242774 | ||
| 996 | ‡2 LC|n 89663272 | ||
| 996 | ‡2 LC|nr 89014577 | ||
| 996 | ‡2 ISNI|0000000036642399 | ||
| 996 | ‡2 ISNI|0000000394309668 | ||
| 996 | ‡2 ISNI|0000000037664223 | ||
| 996 | ‡2 ISNI|0000000102498218 | ||
| 996 | ‡2 SUDOC|061783153 | ||
| 996 | ‡2 BIBSYS|90112967 | ||
| 996 | ‡2 LC|no2006006751 | ||
| 996 | ‡2 J9U|987007453564205171 | ||
| 996 | ‡2 LC|no 92017963 | ||
| 996 | ‡2 BIBSYS|3099171 | ||
| 996 | ‡2 NUKAT|n 2015169742 | ||
| 996 | ‡2 ISNI|0000000046791769 | ||
| 996 | ‡2 ISNI|0000000366211663 | ||
| 996 | ‡2 ISNI|0000000021553879 | ||
| 996 | ‡2 LC|n 85804786 | ||
| 996 | ‡2 SUDOC|255419112 | ||
| 996 | ‡2 BIBSYS|90298422 | ||
| 996 | ‡2 ISNI|0000000077674418 | ||
| 996 | ‡2 CAOONL|ncf10976917 | ||
| 996 | ‡2 LC|n 80094466 | ||
| 996 | ‡2 BNF|14592974 | ||
| 996 | ‡2 ISNI|000000003384514X | ||
| 996 | ‡2 J9U|987007355654305171 | ||
| 996 | ‡2 LC|n 84047160 | ||
| 996 | ‡2 SUDOC|168721902 | ||
| 996 | ‡2 BIBSYS|90784260 | ||
| 996 | ‡2 ISNI|0000000408441345 | ||
| 996 | ‡2 ISNI|0000000500621699 | ||
| 996 | ‡2 LC|no2007117777 | ||
| 996 | ‡2 W2Z|11018288 | ||
| 996 | ‡2 ISNI|0000000043352170 | ||
| 996 | ‡2 CAOONL|ncf11300401 | ||
| 996 | ‡2 ISNI|0000000383182702 | ||
| 996 | ‡2 DBC|87097990066277 | ||
| 996 | ‡2 LC|n 85810092 | ||
| 996 | ‡2 J9U|987007426172105171 | ||
| 996 | ‡2 LC|n 96803379 | ||
| 996 | ‡2 SUDOC|153442999 | ||
| 996 | ‡2 NII|DA06310361 | ||
| 996 | ‡2 LC|nr2001000131 | ||
| 996 | ‡2 J9U|987007342063405171 | ||
| 996 | ‡2 NTA|068907508 | ||
| 996 | ‡2 NII|DA10589036 | ||
| 996 | ‡2 NUKAT|n 2017181844 | ||
| 996 | ‡2 BNE|XX4911588 | ||
| 996 | ‡2 ISNI|0000000033520927 | ||
| 996 | ‡2 LC|n 2016054541 | ||
| 996 | ‡2 LC|nb2010005812 | ||
| 996 | ‡2 ISNI|0000000388314989 | ||
| 996 | ‡2 ISNI|0000000034207377 | ||
| 996 | ‡2 ISNI|0000000037833082 | ||
| 996 | ‡2 ISNI|0000000041178690 | ||
| 996 | ‡2 LC|n 2001008796 | ||
| 996 | ‡2 DNB|134314719 | ||
| 996 | ‡2 LC|no2008014877 | ||
| 996 | ‡2 LC|n 88609272 | ||
| 996 | ‡2 LC|n 89625392 | ||
| 996 | ‡2 LC|n 2003087185 | ||
| 996 | ‡2 J9U|987007352794705171 | ||
| 996 | ‡2 J9U|987007440798105171 | ||
| 996 | ‡2 ISNI|0000000498176492 | ||
| 996 | ‡2 LC|n 80096309 | ||
| 996 | ‡2 BNF|12275773 | ||
| 996 | ‡2 RERO|A002928376 | ||
| 996 | ‡2 RERO|A002928377 | ||
| 996 | ‡2 LC|no2024101969 | ||
| 996 | ‡2 LC|no2019110459 | ||
| 996 | ‡2 BIBSYS|11018288 | ||
| 996 | ‡2 BIBSYS|90752224 | ||
| 996 | ‡2 LC|n 89648631 | ||
| 996 | ‡2 LC|n 94009341 | ||
| 996 | ‡2 BNC|981060950364706706 | ||
| 996 | ‡2 NUKAT|n 2017087522 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
